Phase 1 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People with a confirmed solid tumour diagnosis (Part A) who have already tried all available treatments known to help their condition, or for whom no proven treatment options exist.
• People with a confirmed solid tumour diagnosis (Part B) whose cancer has continued to grow or who could not tolerate standard treatments, and who have received no more than 3 previous treatment courses (not counting certain pre- or post-surgery treatments or a specific cell-based therapy called tumour-infiltrating lymphocytes). A genetic test result for a protein called BRAF must be available before joining.
• People who are generally well enough to carry out light activity and care for themselves, rated 0 or 1 on a standard health scale used in cancer trials (called ECOG performance status).
• People who have at least one measurable area of cancer located outside the brain or spinal cord, as seen on scans.
• People aged 18 years or older.
• People whose organs (such as kidneys and liver) are functioning adequately (confirm with trial site for specific requirements).
• People whose life expectancy is at least 3 months at the time of starting the trial, in the opinion of the treating doctor.
• People whose side effects from previous cancer treatments have mostly resolved to mild or no symptoms before joining, with some exceptions allowed for hair loss, nerve-related symptoms, and certain menstrual changes.

Who may not be able to join:

• People with active brain or spinal cord cancer, untreated cancer that has spread to the brain, or cancer affecting the lining of the brain — although people with brain metastases that are not causing symptoms may still be considered if radiation or surgery was completed at least 2 weeks before starting the trial, and they have been off steroids for at least 7 days and off or on stable doses of anti-seizure medication for at least 7 days (confirm with trial site).
• People with an immune system disorder, or those who have been taking immune-suppressing medications — including steroid doses higher than a low daily threshold — within 7 days before starting the trial.
• People who have received other cancer treatments within 28 days (or within 5 half-lives of that treatment, whichever is shorter) before starting the trial, or who have had extensive radiation therapy including whole-brain radiation within 2 weeks before starting.
• People who have previously had an organ transplant or a stem cell transplant.
• People taking blood-thinning medications that cannot be safely paused if a medical procedure such as a biopsy becomes necessary, in the opinion of the treating doctor.
• Women who are pregnant, breastfeeding, or who plan to become pregnant or breastfeed during the trial or within 4 months after the last dose of the trial treatment.

Important: Always verify eligibility with the trial site directly before applying.